Dear Partner,
We are pleased to offer investors access to a uniquely positioned company in the fast-growing U.S. insect protein market.
The notes provide:
A Target MOIC between 6.9x to 9.6x
Exit target in 2029
IRR 62% to 76% p.a.
The underlying strategy provides investors exposure to a capital-efficient U.S. agribiotech platform commercializing Black Soldier Fly (BSF) protein through high-quality, fully traceable supply chains designed to meet the growing demand for secure and transparent agricultural inputs.
Investments into a revenue-first, capital-light business model with wide opportunities for growth in the protein markets.
We believe this opportunity may complement client portfolios seeking early revenue generation, EBITDA positive investment, and high growth potential.
We would be delighted to provide access to the data room (subject to NDA) or arrange a presentation at your convenience. Competitive partnership terms are available for professional intermediaries.
Please let us know a suitable time to connect.
Contact us
Kind regards,
Hervé Croset
Founding Partner
Bridgeline Capital Partners SA
[email protected]